Neurocrine biosciences presents data at mds international congress of parkinson's disease and movement disorders® demonstrating comparable improvement over time in tardive dyskinesia severity and impact following treatment with ingrezza® (valbenazine) capsules

San diego , aug. 29, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presented findings from a data analysis of kinect®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia (td) severity and awareness/distress as measured by the abnormal involuntary movement scale (aims) and patient-reported td impact as measured by the trajectories of tardive dyskinesia impact scale (tdis). the data (poster #657) was presented at the mds international congress of parkinson's disease and movement disorders® in copenhagen, denmark.
NBIX Ratings Summary
NBIX Quant Ranking